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The first titin
(c.59926+ 1G>A) founder
mutation associated with
dilated cardiomyopathy
Truncating variants in the gene encoding titin
(TTNtv) are found in 13–25% of dilated
cardiomyopathy (DCM) cases.1,2 In DCM
patients, TTNtv are associated with early
arrhythmic risk, composed of atrial fibril-
lation (AF), non-sustained and/or sustained
ventricular tachycardia.3 TTNtv in the A-
band region, or in constitutively expressed
exons of TTN, are generally believed to be
pathogenic, but assigning pathogenicity can
be challenging because TTNtv are also found
in control populations.4
Here we describe the TTN c.59926+1G
>A splice-site variant located in the A-
band (chr2:179456704C>T, build GRCh37;
NM_001267550.2 reference sequence) that
we have identified in multiple probands
with DCM. Written informed consent was
obtained from all participants following local
medical ethics committee guidelines. Our
study and all experiments conformed with
the principles of the Declaration of Helsinki.
A B
Figure 1 Geographic map of the Netherlands showing the distribution of 30 carriers and 36 grandparents. (A) Carriers’ places of residence.
(B) Birthplaces of the grandparents of carriers of the oldest generations from the different families. The six common ancestors linking seven of
the 10 families all originated from a small area in the southern part of the province of Overijssel, indicated by the red circle (10 km radius).
The Exome Aggregation Consortium dataset
(ExAC) and the Genome of the Netherlands
database (GoNL) were used as control popu-
lations. To study a potential founder effect, we
analysed 11 microsatellite markers surround-
ing TTN and performed genealogy research.
The age of the mutation was calculated as
described previously.5
Clinical data were collected retrospectively
from 11 probands, 20 mutation-positive and
17 mutation-negative family members. Sub-
jects were diagnosed with DCM when they
had a reduced left ventricular ejection frac-
tion (<45%) and a widened ventricle (>117%
of predicted). In the absence of information
on end-diastolic diameter, length or weight,
DCM was noted when it was declared DCM
by the cardiologist. We calculated the com-
bined LOD score using linkage programme
GRONDLOD and taking into account an
80% penetrance. Frequencies are expressed
as numbers and percentages and continuous
variables as mean± standard deviation. The
Mann–Whitney U test was used for between-
group comparisons and Fisher’s exact test for
comparing frequencies. Data were analysed
using SPSS version 23 (IBM Corp., Armonk,
NY, USA). A P-value <0.05 was considered
statistically significant.
TTN c.59926+ 1G>A was identified in
18 family members and a further two were
obligate carriers. In total, we studied 31
carriers (11 probands, 20 family members)
and 17 non-carriers. One proband had a
second pathogenic SCN5A (c.4213G>C)
variant. TTN c.59926+1G>A was found
only once in 966 alleles in GoNL (0.1%)6 and
was not present in ExAC.7 Haplotype analysis
of nine probands and seven family members
revealed a shared region of approximately
4Mb, indicating a common ancestor. We
calculated the mutation to be 300–580 years
old. Most carriers, and the grandparents
of the oldest generation carriers from the
different families, originated from the eastern
part of the Netherlands (Figure 1). Genealogy
going back five to nine generations in seven
families revealed three pairs of common
ancestors, all born within a 10 km radius
(Figure 1B). Segregation analysis yielded a
combined LOD score of 3.6, strong evidence
that this mutation is pathogenic.
One obligate carrier was not included
in the analyses as additional clinical data
were unavailable because the first symptom
was sudden cardiac death. The predominant
finding in mutation carriers was DCM (67%;
20/30; mean age of onset 49±14 years).
Atrial tachyarrhythmias were observed in
65% of DCM patients (13/20), with (paroxys-
mal) AF [(p)AF] or paroxysmal atrial flutter
most frequently observed (60%; 12/20)
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Clinical characteristics of 30 TTN c.59926+ 1G>A mutation carriers and 17 mutation negative family
members
TTN c.59926+ 1G>A + TTN c.59926+ 1G>A –
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
DCM (n= 20) No DCM (n= 10) No DCM (n= 17)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age at diagnosis/evaluation, years 49±14 47±19 49± 10
Proband 11 (55%) 0 (0%) 0 (0%)
Male 14 (70%) 1 (10%) 13 (62%)
LVEFa, % 26±11 53± 3* 57± 4*
LVEDDa, mm 63± 7 51± 6† 50± 4†
Atrial tachyarrhythmias 13 (65%) 3 (30%) 0 (0%)‡
(Paroxysmal) atrial fibrillation/flutter 12 (60%) 3 (30%) NA
Ventricular arrhythmias 9 (45%) 1 (10%) 0 (0%)
Non-sustained ventricular tachycardia 5 (25%) 1 (10%) NA
Ventricular tachycardia/fibrillation 4 (20%) 0 (0%) NA
Out-of-hospital cardiac arrest 2 (10%) 0 (0%) 0 (0%)
ICD implantation 9 (45%) 0 (0%) 0 (0%)
Appropriate ICD therapy 4 (20%) NA NA
Risk factors 11 (55%) 6 (60%) 3 (18%)
Hypertension 7 (35%) 2 (20%) 2 (12%)
Diabetes mellitus 2 (10%) 0 (0%) 0 (0%)
Dyslipidaemia 3 (15%) 0 (0%) 2 (12%)
Coronary artery disease 2 (10%) 1 (10%) 0 (0%)
Obesity 1 (5%) 2 (10%) 1 (6%)
Otherb 3 (15%) 1 (10%) 0 (0%)
DCM, dilated cardiomyopathy; ICD, implantable cardioverter-defibrillator; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; NA, not
applicable; TTN, titin.
aMeasurements are based on the lowest measured ejection fraction and the largest end-diastolic diameter.
bComposition of chemotherapy, history of excess alcohol consumption, and severe mitral valve insufficiency.
*LVEF is available from five carriers and six non-carriers. In four carriers, left ventricular function is described as normal, of which one is described as >55%. In another carrier
left ventricular function is described as moderate (45–55%). In the other 11 non-carriers left ventricular function is described as normal.
†LVEDD is missing from one carrier and available from 13 non-carriers; in the other four non-carriers, LVEDD is described as normal.
‡Holter monitoring only performed in three non-carriers.
(Table 1). One DCM patient had collapsed
due to an atrioventricular nodal re-entry
tachycardia (AVNRT), which converted to
sinus rhythm after administration of adeno-
sine. Of note, left atrial enlargement was
observed on echocardiography 6months
before the AVNRT. In three patients (p)AF
preceded the DCM phenotype (by 11, 12,
and 14 years). Males were over-represented
in the DCM group compared to carriers with
no DCM (P= 0.003).
To evaluate if the frequent occurrence
of (p)AF occurred with left atrial widening,
we collected information on atrial size [see
Supplementary material online, Table S1, for
risk factors, age at onset of (p)AF, DCM, and
age at left atrial measurements]. Interestingly,
in the DCM group, eight subjects had (p)AF
without left atrial dilatation, including four
without risk factors that could attribute to
the development of (p)AF. In the carrier
group without DCM, three subjects (30%)
had (p)AF: two had no atrial dilatation and
one had atrial dilatation measured while AF
was her underlying rhythm (Figure 2).
Two carriers suffered from an aborted
cardiac arrest and one obligate carrier
died suddenly (aged 58, 75, and 33 years,
respectively). Autopsy in the deceased
patient revealed signs of cardiomyopathy. An
implantable cardioverter-defibrillator (ICD)
was implanted in nine carriers: two in the con-
text of secondary intervention and seven for
primary prevention. Four ICD carriers (44%;
4/9) received appropriate treatment (three
times ICD shock and one time antitachycardia
pacing) within 1–4 years after implantation.
Two patients underwent a heart trans-
plantation. Hypertension, diabetes mellitus,
and dyslipidaemia seemed more frequently
present in the DCM group, but significant
differences could not be demonstrated given
our small sample. Another potential influence
masking the effect of the cardiovascular risk
factors could be that the carrier group with
no DCM consisted almost entirely of women.
An additional stressor was reported in
six carriers. The obligate carrier who died
suddenly was reported to have used excessive
amounts of alcohol, which was also suggested
as a possible cause of DCM in another car-
rier. In two other carriers, a history of an
infectious period preceded the development
of severe left ventricular impairment. One
required intra-aortic balloon support, with
myocarditis suspected but not evaluated, and
his cardiac function largely recovered. In the
other, myocardial biopsy was negative for
cardiotropic viruses, but his left ventricular
function remained poor (ejection fraction
18%). In another carrier, severe DCM (ejec-
tion fraction 15%) became apparent after
anthracycline therapy. Finally, one proband
with DCM carried an additional pathogenic
SCN5A mutation. He had no spontaneous
type 1 Brugada ECG but did have SCN5A-
related features: a right bundle branch block
and delayed atrioventricular conduction (PR
interval 330ms). Taken together, these data
support a multiple-hit model in which a ‘sec-
ond genetic hit’ or additional environmental
stressor is required to develop overt disease.
Dilated cardiomyopathy caused by TTNtv
has been reported to respond relatively well
to treatment,8 which we also observed in
some carriers. Cardiac function in one patient
recovered after a short period after cardio-
genic shock due to a suspected myocarditis.
Two DCM patients responded well to treat-
ment after a follow-up of 6 and 4 years
(increases in ejection fraction of 20% to 45%
© 2017 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Venn diagrams of carriers with and without dilated cardiomyopathy (DCM) showing the presence of risk factors, atrial arrhythmias,
and atrial dilatation. AVNRT, atrioventricular nodal re-entry tachycardia.
and 43% to 50%, and decreases in left ven-
tricular end-diastolic dimensions of 65mm to
53mm and 60 to 47mm, respectively).
The occurrence of (p)AF without or pre-
ceding DCM was interesting. To evaluate if
this predisposition to (p)AF is inherent to this
specific mutation or to TTNtv in general, we
looked at age at diagnosis of DCM and (p)AF
for carriers of 16 other TTNtv residing in
constitutively expressed exons. We evaluated
53 carriers (16 probands and 37 family mem-
bers) and found 19 asymptomatic carriers,
6 with only (p)AF (11%), 3 in whom (p)AF
preceded DCM (6%) (by 1, 4, and 22 years),
11 in whom (p)AF was diagnosed the same
year as DCM (21%), 6 who developed (p)AF
after diagnosis of DCM (11%), and 8 with
only DCM (15%). Together with the results
from our cohort, this indicates that (p)AF
is an important part of the clinical disease
spectrum caused by TTNtv, even if gross
structural abnormalities are not yet present.
Conclusion
We evaluated the clinical and genetic back-
ground of the largest cohort reported
to date of carriers with an identical TTN
(founder) variation believed to be pathogenic
because of segregation with the disease
(LOD score 3.6). To our knowledge, this is
the first time a founder effect in TTN has
been associated with cardiomyopathy. The
phenotype is characterized by DCM and
atrial tachyarrhythmias, specifically (p)AF. As
(p)AF could be the first symptom, clinicians
could consider performing ambulatory ECG
(Holter) monitoring in asymptomatic car-
riers during cardiac follow-up. A role for
TTN in the aetiology of AF is further sup-
ported by a recent genome wide association
study.9
In addition to atrial arrhythmias, TTNtv
may also increase susceptibility for ventricu-
lar arrhythmias because two carriers had an
aborted cardiac arrest, one obligate carrier
died suddenly, and nearly half of the ICD
carriers had received appropriate ICD ther-
apy (4/9). Roberts et al.1 also showed that
TTNtv-positive DCM patients experienced
sustained ventricular tachycardia more often
than TTNtv-negative DCM patients.
We also observed male predominance in
DCM (93% of males had DCM vs. 40% of
females), which seems counter-intuitive given
autosomal dominant inheritance. However, in
a large cohort of carriers of a different TTNtv
(n= 94), males also seemed more severely
affected with respect to rates of heart trans-
plantations, implantation of left ventricular
assist devices, and death from cardiac causes.2
Since our cohort is relatively homogeneous
(identical mutation), the significant sex differ-
ence underscores the important role of sex
in the development of DCM in TTNtv. While
we still do not understand which mecha-
nisms underlie the incomplete penetrance,
there are some indications from our cohort
that additional stressors (cardiovascular risk
factors, alcohol, myocarditis, chemotherapy,
or an additional mutation, male sex) may
trigger the development of DCM in a heart
that is already susceptible by a TTNtv. These
observations need systematic investigation in
larger cohorts of different TTNtv or in a later
stadium when more carriers of this mutation
are identified.
Supplementary Information
Additional Supporting Information may be
found in the online version of this article:
Table S1. Shared haplotype surrounding
the TTN mutation.
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